N. A. Dovzhenko
N. A. Dovzhenko has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Gintsburg
National Research Center for Epidemiology and Microbiology Named after the Honorary Academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia
1 shared publication - Alina S. Bandelyuk
National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow
1 shared publication - Denis Yu. Logunov
Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named After Honorary Academician N. F. Gamaleya”, the Ministry of Health of the Russian Federation, Moscow 123098, Russia
1 shared publication - Dmitrii N. Shcherbinin
Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
1 shared publication - Ilias B. Esmagambetov
N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation
1 shared publication - Lyudmila V. Verkhovskaya
National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow
1 shared publication
Latest Publications
- Open Access
- 21 March 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 7-21
Safety, reactogenicity, and immunogenicity of a viral vector vaccine against influenza A: Phase I open clinical trial
INTRODUCTION. The development of universal influenza vaccines based on conserved influenza virus antigens is a promising strategy for preventing pandemic influenza. Recombinant vaccines based on adenoviral vectors have high antiviral potential and have proven their effectiveness during the COVID-19 pandemic. In this regard, the development and clinical evaluation of a viral vector vaccine against influenza A seem relevant.AIM. The aim was to evaluate the safety, reactogenicity, and immunogenicity of a broad-spectrum viral vector vaccine against influenza A after a single intranasal administration in healthy volunteers.MATERIALS AND METHODS. This clinical trial studied the GamFluVac recombinant human adenovirus serotype 5 (rAd5)-based vaccine against influenza A (National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya). The clinical trial enrolled 36 volunteers. The follow-up period was 28 days. The safety assessment of the viral vector vaccine was based on the incidence, nature, and severity of adverse events (AEs) after a single intranasal administration at doses of 2.5×1010 (Group 1), 1.0×1011 (Group 2), and 2.5×1011 (Group 3) viral particles. Immunogenicity was evaluated by measuring serum IgG antibodies against influenza A (H5N2) by enzyme immunoassay on Day 0 and Day 28.RESULTS. No serious or severe AEs were reported during the clinical trial. Most AEs associated with the vaccine manifested as respiratory disorders, abnormal blood findings, and general disorders (elevated body temperature, headache, chills, malaise, arthralgia, and myalgia). Statistically significant differences (p=0.0285) were identified in the incidence of general disorders and administration site conditions in Group 1 (0%), Group 2 (16.7%), and Group 3 (33.3%). Group 3 demonstrated the highest increase in the geometric mean titres of specific IgG antibodies (2.8 times the baseline) on Day 28. In this group, 100% of volunteers had a ≥2-fold seroconversion rate, and 41.7% of volunteers had a ≥4-fold seroconversion rate.CONCLUSIONS. This phase I clinical trial of the GamFluVac viral vector vaccine against influenza A demonstrated the immunogenicity and favourable safety profile of the vaccine after a single intranasal administration.
- 21 March 2025
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 25 (1) , 7-21
Open AccessSafety, reactogenicity, and immunogenicity of a viral vector vaccine against influenza A: Phase I open clinical trial
INTRODUCTION. The development of universal influenza vaccines based on conserved influenza virus antigens is a promising strategy for preventing pandemic influenza. Recombinant vaccines based on adenoviral vectors have high antiviral potential and have proven their effectiveness during the COVID-19 pandemic. In this regard, the development and clinical evaluation of a viral vector vaccine against influenza A seem relevant.AIM. The aim was to evaluate the safety, reactogenicity, and immunogenicity of a broad-spectrum viral vector vaccine against influenza A after a single intranasal administration in healthy volunteers.MATERIALS AND METHODS. This clinical trial studied the GamFluVac recombinant human adenovirus serotype 5 (rAd5)-based vaccine against influenza A (National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya). The clinical trial enrolled 36 volunteers. The follow-up period was 28 days. The safety assessment of the viral vector vaccine was based on the incidence, nature, and severity of adverse events (AEs) after a single intranasal administration at doses of 2.5×1010 (Group 1), 1.0×1011 (Group 2), and 2.5×1011 (Group 3) viral particles. Immunogenicity was evaluated by measuring serum IgG antibodies against influenza A (H5N2) by enzyme immunoassay on Day 0 and Day 28.RESULTS. No serious or severe AEs were reported during the clinical trial. Most AEs associated with the vaccine manifested as respiratory disorders, abnormal blood findings, and general disorders (elevated body temperature, headache, chills, malaise, arthralgia, and myalgia). Statistically significant differences (p=0.0285) were identified in the incidence of general disorders and administration site conditions in Group 1 (0%), Group 2 (16.7%), and Group 3 (33.3%). Group 3 demonstrated the highest increase in the geometric mean titres of specific IgG antibodies (2.8 times the baseline) on Day 28. In this group, 100% of volunteers had a ≥2-fold seroconversion rate, and 41.7% of volunteers had a ≥4-fold seroconversion rate.CONCLUSIONS. This phase I clinical trial of the GamFluVac viral vector vaccine against influenza A demonstrated the immunogenicity and favourable safety profile of the vaccine after a single intranasal administration.